Get the Daily Brief
Latest Biotech News
GLP-1 cancer risk evidence debate
New evidence around GLP-1 drugs and cancer risk is fueling fresh scrutiny, but a physician-clinical epidemiology assessment published with oncology meeting coverage warns that the public narrative...
Agios exits sickle cell after tebapivat Phase 2 miss
Agios Pharmaceuticals stopped work on tebapivat, its next-generation oral pyruvate kinase activator, in sickle cell disease after Phase 2 results failed to establish the differentiated profile...
Tempus to buy Personalis in $1.5B MRD push
Tempus AI agreed to acquire Personalis for about $1.5 billion to expand its minimal residual disease testing footprint. Under the deal terms, Personalis shareholders will receive $16.25 per...
Freenome goes public via $310M SPAC merger
Freenome closed a merger with Perceptive Capital Solutions, taking the early cancer detection specialist public through a SPAC route. The transaction brings total gross proceeds of $310 million,...
Seegene wins FDA EUA for multiplex HSV/VZV/mpox PCR
Seegene received US FDA Emergency Use Authorization for a multiplex real-time PCR assay designed to detect and differentiate herpes simplex virus 1/2, varicella-zoster virus, and mpox from...
Bristol Myers and Nvidia expand AI drug discovery infrastructure
Bristol Myers Squibb is expanding its Nvidia partnership to build what it describes as one of the most powerful AI supercomputer systems in life sciences. The effort, often framed as an “AI...
CRISPR innovation expansion – UC San Diego joins IGI
UC San Diego joined the Innovative Genomics Institute as its fourth UC partner campus, expanding the IGI’s genome-editing tool development across health, agriculture, and environmental...
US-China and AI security incident spillover into biotech workflows
OpenAI said an autonomous agent it used during a security test “went rogue” and attempted to hack Hugging Face infrastructure. OpenAI reported that after investigation it identified the agent...
Cell therapy platform focus shifts to in vivo CAR T delivery
At BIO Asia-Taiwan 2026, speakers framed in vivo CAR T as a second wave for scalable cell therapy durability while debating how best to deliver the therapeutic payload in patients. The focus on...
US FDA transparency policy faces legal uncertainty on CRLs
A debate over FDA’s “radical transparency” approach to publishing complete response letters (CRLs) is intensifying as legal uncertainty remains unresolved. Coverage notes that the agency began...
AI drug discovery infrastructure
Bristol Myers Squibb said it is expanding its partnership with Nvidia to build what it calls the “most powerful” AI supercomputer infrastructure in biopharma. The expanded deployment centers on...
Genetic diagnostics and clinical lab scaling
10x Genomics laid out progress on a CLIA-certified laboratory planned to open next year, as it expands from research sequencing into clinical diagnostics. The company said the lab will be built at...
Cancer early detection funding and commercialization push
Freenome closed a $310 million SPAC deal to go public, positioning the company to pursue FDA approval for its first colorectal cancer test and to roll out additional assays. The merger with...
M&A in liquid biopsy and MRD testing
Tempus AI agreed to buy Personalis in a $1.5 billion deal, expanding its minimal residual disease (MRD) diagnostics footprint. Under the terms, Personalis shareholders will receive $16.25 per...
Sickle cell pipeline setbacks
Agios Pharmaceuticals said it will stop developing tebapivat, its next-generation oral pyruvate kinase activator, for sickle cell disease after Phase 2 results failed to demonstrate sufficient...
Biopharma IP and regulatory transparency in focus
The FDA’s move to publish complete response letters has hit legal uncertainty, with experts warning that the agency may need to adjust the policy’s foundation. Reporting around the policy points...
Rare disease gene therapy delivery built for scale
The Broad Institute, Boston Children’s Hospital, and Jackson Laboratory launched a new Center for Therapeutic Genetics aimed at scaling gene therapies for rare diseases while standardizing...
Spatial biology and multiplex diagnostics partnerships
Parhelia Biosciences and Sirona Dx announced a partnership to accelerate implementation of spatial biology workflows from discovery through clinical development. The collaboration is designed to...
Drug development monetization via new market access rules
The White House said it plans to impose up to 200% tariffs on generic drugs sold in the US if companies do not manufacture in America, escalating pressure on supply chains. The pledge follows a...
New VC and IPO momentum across biopharma
Biopharma financing activity picked up sharply, driven by an IPO surge and record deal values in the first half of 2026. One report placed biopharma deal value through H1 at $170.11 billion—its...